Current disease modifying approaches to treat Parkinson&apos;s disease by Lindholm, Dan et al.
REVIEW
Current disease modifying approaches to treat Parkinson’s
disease
Dan Lindholm1,2 • Johanna Ma¨kela¨1,2 • Valentina Di Liberto3 • Giuseppa Mudo`3 •
Natale Belluardo3 • Ove Eriksson1 • Mart Saarma4
Received: 5 October 2015 / Revised: 18 November 2015 / Accepted: 23 November 2015 / Published online: 30 November 2015
 Springer International Publishing 2015
Abstract Parkinson’s disease (PD is a progressive neu-
rological disorder characterized by the degeneration and
death of midbrain dopamine and non-dopamine neurons in
the brain leading to motor dysfunctions and other symp-
toms, which seriously influence the quality of life of PD
patients. The drug L-dopa can alleviate the motor symp-
toms in PD, but so far there are no rational therapies
targeting the underlying neurodegenerative processes.
Despite intensive research, the molecular mechanisms
causing neuronal loss are not fully understood which has
hampered the development of new drugs and disease-
modifying therapies. Neurotrophic factors are by virtue of
their survival promoting activities attract candidates to
counteract and possibly halt cell degeneration in PD. In
particular, studies employing glial cell line-derived neu-
rotrophic factor (GDNF) and its family member neurturin
(NRTN), as well as the recently described cerebral dopa-
mine neurotrophic factor (CDNF) and the mesencephalic
astrocyte-derived neurotrophic factor (MANF) have shown
positive results in protecting and repairing dopaminergic
neurons in various models of PD. Other substances with
trophic actions in dopaminergic neurons include neu-
ropeptides and small compounds that target different
pathways impaired in PD, such as increased cell stress,
protein handling defects, dysfunctional mitochondria and
neuroinflammation. In this review, we will highlight the
recent developments in this field with a focus on trophic
factors and substances having the potential to beneficially
influence the viability and functions of dopaminergic
neurons as shown in preclinical or in animal models of PD.
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Introduction
Parkinson’s disease (PD) is after Alzheimer’s disease the
second most common neurodegenerative disorder and
affects about 1 % of the elderly population. Currently there
are 7–8 million patients with PD. A known risk factor for
PD is age suggesting that the prevalence of PD is likely to
increase among the aging population worldwide. The debut
of the disease is usually around the age of 60 with a pro-
gress of symptoms over time. Like other human diseases
PD has a subclinical phase and a clinical phase with overt
symptoms that bring the patient to the doctor. The clinical
manifestation of PD is associated with severe motor
symptoms such as resting tremor, rigidity, hypokinesia and
gait dysfunctions. This is associated with the decline in
dopamine levels, and with the degeneration and loss of
dopaminergic neurons in the substantia nigra pars com-
pacta (SNpc) leading to alterations in nigrostrial neuronal
circuitries. However, patients afflicted with PD have also
various non-motor symptoms such as impairment of smell,
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autonomic dysfunctions, depression, lack of motivation,
sleep disorders and later on reduced cognitive abilities and
dementia. The ultimate goal of a sustainable disease-
modifying treatment in PD is to slow down or even stop
disease progression by addressing the degenerative process
in all different types of neurons. Ideally, in disease-modi-
fying therapies degenerating neurons can be regenerated
and the functional activity of the remaining neurons gets
enhanced. It is important to emphasise that neuroprotective
strategies should be directed to the presymptomatic phase
of the disease so as to restrain the continuous loss of viable
neurons in PD. For this, the development of novel
biomarkers and diagnostics are urgent and prerequisites for
a better treatment of PD in the future.
Basic research into the genetics and pathophysiology of
PD has increased our understanding about the fundamental
processes causing neurodegeneration and cell dysfunctions
and helped to identify novel and promising targets for
neuroprotection. Here, we will discuss possible neuropro-
tective strategies to target cellular events occurring in PD
such as increased endoplasmic reticulum (ER) stress,
mitochondria dysfunctions, protein aggregation as well as
neuroinflammation. We also review recent developments in
the use of neurotrophic factors and disease-modifying
drugs with potentials to slow the disease process and to
provide recovery of neuronal functions in PD.
Genetics and pathogenetic mechanisms in PD
Despite intense research on pathogenetic mechanisms, we
still do know little about the primary insult(s) that trigger
changes in vulnerable neurons in PD at the initial stage of
the disease. However, there is increasing number of genes
that have been identified that predispose to motor symp-
toms and PD. Studies of the genetics of PD have revealed
alterations in specific genes and proteins that are linked to
the disease [1, 2]. These include mutations in the genes for
a-synuclein (a-syn) also called PARK1, Parkin/PARK2,
PINK-1/PARK6, DJ-1/PARK7, LRRK2/PARK8 and oth-
ers (see Table 1). It is interesting to note that mutations in
the a-syn were the first that clearly linked genes to PD. The
functions of these gene products are associated with
specific intracellular pathways and cell organelle systems
that contribute to the pathophysiology of PD (Table 1).
Around 5–10 % of all PD cases are familial forms, whereas
the majority of patients have a sporadic form of PD with no
obvious or so far identified genetic cause.
Pathogenetic mechanisms in PD include mitochondrial
dysfunctions, calcium dysregulation, altered cell signaling,
increased oxidative and ER stress, as well as a disturbed
protein handling (proteostasis) with the accumulation and
aggregation of unfolded or mutant proteins accompanied
by defects in autophagy or in the ubiquitin–proteasome
system (UPS) [3–5]. Moreover, an increased neuroinflam-
mation and a reduced trophic support in the brain are also
thought to contribute to PD. The selective vulnerability of
dopamine neurons in SNpc in PD was recently related to an
intrinsic pacemaker activity driven by a specific subtype of
L-type voltage-dependent Ca2? channels expressed by
these neurons [6]. The dopaminergic neurons are thought to
have a high-energy demand reflected by an enhanced rate
of oxidative phosphorylation and with increased production
of reactive oxidative species (ROS) causing oxidative
stress [7]. A better understanding of the disease-causing
processes in PD is a prerequisite for the development of
neuroprotective treatments and novel disease-modifying
agents in PD.
Protein aggregation and misfolding in PD
PD is characterized by the presence of intraneuronal
inclusions identified in post-mortem tissue and named
Lewy bodies in cell soma and Lewy neurites in neuronal
processes (reviewed in 8). The protein aggregates contain
misfolded a-syn which is a presynaptic protein with a
physiologic role linked to regulation of vesicle turnover
and neurotransmission [8, 9]. a-syn is normally present as
monomer in cells but mutant or misfolded a-syn accumu-
lates as oligomers or filaments in different neuronal
compartments, in axons, in the cell soma and in dendrites
[8, 9]. Large-scale proteomic studies have shown that
monomeric and oligomeric a-syn can interact with a
specific set of cellular proteins [10]. a-syn is also known to
interact with intracellular membranes and organelles which
may help to explain its multiple actions in pathophysio-
logical processes leading to PD (see below). The
significance of a-syn in pathogenesis of PD is revealed by
mutations in a-syn and by a-syn gene duplication or trip-
lication which were also shown to cause PD [1, 2].
a-syn is usually degraded by autophagy–lysosome sys-
tem including chaperon-mediated autophagy [11] and
disturbances in autophagy-lysosomal system can contribute
to its toxicity and accumulation in the cell and triggering
ER stress [12, 13]. A recent development regarding PD is
the finding that about 5–10 % of PD patients, depending on
the population backgroundis estimated to carry mutations
in the lysosomal enzyme, glucocerebrosidase (GBA)
making it a major risk factor for PD [14]. Homozygous
GBA mutations cause Gaucher disease (GD) a lysosomal
storage disorder with accumulation of the sphingolipid,
glucosylceramide that affects different organs [14]. A
major neurologic complication in GD is Parkinsonism with
clinical signs and Lewy body inclusions largely indistin-
guishable from sporadic PD. Heterozygote GD patients
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have an increased frequency of developing PD, and bio-
chemical analyses showed reduced GBA enzyme activity
in substantia nigra in PD patients with GBA mutations as
well as in sporadic PD [14, 15]. Recent data suggest that
accumulation of lipid substrates does not occur in brains of
PD patients with mutant GBA, suggesting other mecha-
nisms for neurodegeneration [16]. Studies have shown that
mutant GBA can accumulate in the ER and thereby may
cause ER stress [14]. There is further a functional rela-
tionship between GBA and a-syn levels in the cell [17] that
may provide novel targets for neuroprotection.
To understand the sequel and neuropathology of spo-
radic PD, Braak and colleagues characterized up to six
stages of the disease based upon immunoreactive a-syn
neuronal inclusions in autopsy material from PD patients
[18]. a-syn inclusions were initially observed in regions
such as the olfactory bulb and the dorsal motor nucleus of
the vagus nerve in the brain stem, thereafter spreading to
other neurons in the brain stem, amygdala, cortex and
striatum [18, 19]. Moreover, a-syn aggregates have been
detected in enteric neurons even before the diagnosis of
motor symptoms in PD patients. At later stages Lewy
pathology was widespread with worsening of clinical
symptoms in patients and with the decline in dopamine
concentration in the brain. Axonal transport is likely
involved in the spreading and transfer of a a-syn in the
brain as it follows specific anatomic tracts [9, 20]. There is
also some evidence that a-syn can propagate from cell to
cell via the extracellular space, and misfolded a-syn may
act as a seed for protein aggregation via a prion-like
mechanism [9, 20].
The vagal nerve has a widespread innervation to several
targets including internal organs in the body. Recent
studies have provided some evidence that the gut micro-
biome is altered in PD and related to motor phenotype [21].
It is so far unclear, what pathophysiological roles these
changes may play in the disease and whether such changes
could serve as biomarkers in PD.
Hindrance of a-syn spreading by blocking of extraneu-
ronal a-syn by specific compounds or using immunization
Table 1 Genes associated with familial forms of PD
Locus Gene Inheritance Disorder Function
PARK1,
PARK4
SNCA Autosomal dominant;
sporadic
Early onset PD Involved in synaptic vesicle formation
PARK2 Parkin Autosomal recessive;
sporadic
Juvenile and early onset PD E3 ligase
PARK6 PINK1 Autosomal recessive Early onset PD Mitochondrial kinase
PARK7 DJ-1 Autosomal recessive Early onset PD Involved in oxidative stress response
PARK8 LRRK2 Autosomal dominant;
sporadic
Late onset PD Protein kinase
PARK9 ATP13A2 Autosomal recessive Kufor–Rakeb syndrome P-type transport ATPase
Putative locus/gene
PARK 3 Unknown Autosomal dominant Late onset PD Unknown
PARK5 UCHL1 Autosomal dominant Late onset PD Ubiquitin-protein hydrolase
PARK10 Unknown Unclear Late onset PD Unknown
PARK11 GIGYF2 Autosomal dominant Late onset PD Involved in cellular insulin and insulin-like growth
factor response
PARK12 Unknown Risk factor Late onset PD Unknown
PARK13 Omi/
HTRA2
Autosomal dominant or risk
factor
Late onset PD Mitochondrial-targeted serine protease
PARK14 PLA2G6 Autosomal recessive Early onset dystonia-
parkinsonism
A2 phospholipase
PARK15 FBXO7 Autosomal recessive Early onset parkinsonian E3 ubiquitin protein ligase complex
PARK16 Unknown Risk factor Late onset PD Unknown
PARK17 VPS35 Autosomal dominant Late onset PD Component of the retrograde cargo-selective complex
PARK18 EIF4G1 Autosomal dominant Late onset PD Component of eIF4F complex at the ribosome
GBA Risk factor Early onset PD Lysosomal enzyme
DAT Risk factor Early onset PD Dopamine uptake
Modified from [1, 2]. SNCA a-synuclein, PINK1 PTEN induced putative kinase 1, DJ-1 protein deglycase DJ-1, LRRK2 leucine rich repeat
kinase 2, ATP13A2 ATPase type 13A2, UCHL1 ubiquitin carboxyl-terminal esterase L1, GIGYF2 GBR10 interacting GYF protein 2, Omi/
HTRA2 serine protease HTRA2, mitochondrial, PLA2G6 phospholipase A2, group VI, FBXO7 F-Box protein 7, VPS35 vacuolar protein sorting-
associated protein 35, EIF4G1 eukaryotic translation initiation factor 4 gamma1, GBA beta-glucocerebrosidase, DAT dopamine transporter
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strategies are promising approaches to reduce the burden of
a-syn in the brain to possibly halt the progression of PD
[20, 22]. Preclinical studies along these research lines have
shown promising results [22, 23], and currently various
immunotherapies based upon active (injection of recom-
binant a-syn) and passive immunization (injection of
domain-specific anti-a-syn antibodies) procedures are in
clinical testing or are being planned for PD patients
(Table 2). As reviewed recently the processing, oligomer-
ization and aggregation of intracellular a-syn are also
potential targets for the development of disease-modifying
therapies in PD showing encouraging results [20, 22].
ER stress in PD
The unfolded protein response (UPR) is a conserved cel-
lular process in the endoplasmic reticulum by which the
cells respond to oxidative stress, increased calcium levels
and a disturbed protein homeostasis with the accumulation
of misfolded, aggregated or mutant proteins in the ER that
are normally processed by the proteasome or autophagy
systems [24]. The UPR is usually protective and engages
specific signaling pathways and chaperones to restore cell
homeostasis and protein refolding (Fig. 1). However, pro-
longed and sustained UPR activation can lead to full blow
ER stress with the activation of pathways linked to cell
degeneration and finally triggering cell death [24]. Exper-
imental evidence suggests that UPR regulates the ER stress
of the cell by three different pathways: mRNA degradation
and suppression of further protein synthesis, enhancement
of protein refolding by the induction of ER chaperons and
activation of ER-associated degradation of unfolded pro-
teins. Three ER transmembrane receptors mediate UPR:
inositol-requiring enzyme 1 (IRE1), pancreatic ER kinase-
like ER kinase (PERK) and activating transcription factor 6
(ATF6). These transmembrane receptors are activated in
ER stress by dissociating from an ER chaperone GRP78
(alias BiP) that is associated with several proteins (Fig. 1).
Phosphorylated PERK blocks general mRNA translation
by phosphorylating eukaryotic initiation factor 2a (eIF2 a).
However, transcription factor ATF4 is produced despite
translation initiation block. ATF6 and IRE1 pathways
regulate the expression of ER chaperone genes and IRE1
degrades mRNA and, through spliced X-box binding pro-
tein (XBP1), induces the expression of genes for protein
degradation. At later stages C/EBP-homologous protein
(CHOP) can trigger the apoptotic response.
ER stress is thought to play an important role in the
pathogenesis of neurodegenerative diseases including PD
[25, 26]. Thus the neurotoxins, 6-hydroxydopamine (6-
OHDA) and N-methyl-4-phenyl-1, 2,3,6-tetrahydroyridine
(MPTP) produce oxidative damage with an increased
production of ROS and ER stress in cultured dopaminergic
Table 2 Examples of clinical trials using disease-modifying agents in Parkinsons disease
Conditions Aim of the study Disease group ClinicalTrials.gov
identifier
Comments
AAV2-GDNF bilateral
intraputamental infusions
Safety trial using 4
different doses of
AAV2-GDNF
Advanced PD NCT01621581 Phase I recruiting
Recombinant GDNF
(9–11 mg/ml) intermittent
bilateral intraputamen
infusions
Effect on OFF-state
motor function at
9 months
PD EUCTR2011-
003866-34-GB
Phase II ongoing
Recombinant GDNF
(9–11 mg/ml) intermittent
bilateral intraputamen
infusions
As above comparing
effects at 18 and
9 months of
treatment
PD EUCTR2013-
001881-40-GB
Phase II ongoing
Recombinant PDGF-BB into
brain ventricle using
catheter
Safety trial: infusion
into brain for
2 weeks
Moderate PD NCT00866502 Phase 1 completed: Safe and well tolerated more
studies planned
Pioglitazone daily 15 or
40 mg
Effect on progression
of PD
210 patients
with early
PD
NCT01280123 Phase 2 completed: showed no significant clinical
benefit
Exenatide daily injections
for 12 months
Effect on motor and
cognitive functions
Moderate PD
45 patients
no placebo
group
NCT01174810 Phase 2 completed: clinical improvements at
12 months with persistent effects after 12 months
of drug withdrawal studies planned using slow-
release form of drug
Immunotherapy using
monoclonal anti- a-syn
antibodies (PRX002)
Safety trial effect on
a-syn levels
Normal healthy
subject then
PD patients
NCT02095171
NCT02157714
Phase 1 completed: no adverse effects shown, a-syn
reduced in serum. Now PD patients are recruited
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neurons [27]. Recently, it was shown that UPR markers are
present in post-mortem brain of patients with Lewy body
disease including PD [28]. Furthermore, neurons derived
form induced pluripotent stem cells of PD patients showed
defects in protein handling which was linked to an acti-
vated ER stress response [29]. Development of
neuroprotective substances targeting signaling cascades
linked to ER stress could therefore be of value also in PD.
However, the situation is complex since the three ER sig-
naling cascades serve different functions in the context of
cell viability and a mild cell stress involving the UPR is
likely to be protective [30]. Studies of mice with gene
deleted of different ER stress signaling components
showed that dopaminergic neurons from XBP1 and CHOP
gene deleted mice were resistant against neurotoxins, while
those from ATF6 exhibited an enhanced susceptibility [31].
The role of ER stress and IRE1a and the PERK pathways,
regulating XBP1and CHOP, respectively, warrant further
studies in different PD models.
The link between ER stress and PD has also been sug-
gested by studying familial forms of the disease. Parkin is
an E3 ubiquitin ligase (Table 1) that in a mutant form
induces ER stress with the accumulation of protein
aggregates [32]. One target for Parkin action is the Parkin
associated endothelin-receptor like receptor (Pael-R), a
G-protein-coupled transmembrane protein which when
overexpressed accumulates and causes ER stress in
dopaminergic neurons [32, 33]. Parkin is important for the
normal turnover of dysfunctional mitochondria via selec-
tive autophagy (mitophagy) that links ER stress to
alterations in mitochondrial oxidative phosphorylation and
an increased oxidative stress [33].
Defects in vesicle transport are important mechanisms in
PD, and mutant a-syn was shown to reduce ER to Golgi
trafficking and to aggravate ER stress [34, 35]. A possible
mechanism for a-syn induced ER stress in dopaminergic
neurons was related to the accumulation of toxic a-syn
oligomers within the ER lumen and binding to chaperones
such as Grp78/Bip (see Fig. 1). Recently, a-syn was
localised to a subdomain of ER called mitochondria-asso-
ciated endoplasmic reticulum membrane (MAM) that takes
part among others in the regulation of calcium and lipid
metabolism in the cells [36, 37]. It was further shown that
the disease-causing A30P and A53T mutant a-syn is less
present in MAMs compared with the wild-type protein
suggesting an altered ER–mitochodria cross talk in PD
[37]. Along this line it has been reported that drug agonist
for the r non-opioid intracellular receptor 1 (Sigma-R1)
which is present in MAM can provide neuroprotection in
an animal model of PD [38]. Data showed that the Sigma-
R1 agonist acted partly by increasing the levels of the
neurotrophic factors, brain-derived neurotrophic factor
(BDNF) and glial cell line-derived neurotrophic factor
(GDNF), but additional mechanisms are also possible [38].
Disease-modifying effects of Sigma-R1 agonists have also
been observed in other models of neurodegenerative dis-
ease including Huntington diseases [39]. Interference with
the accumulation of a-syn in the ER and modulation pro-
tein complexes associated with MAM are attractive targets
to consider for further drug development in PD.
Fig. 1 Unfolded protein response and ER stress signaling pathways
in PD. The unfolded protein response (UPR) is a conserved pathway
for regulating protein homeostasis in the cell and it is controlled by
the chaperon GRP78/BIP protein complex in the ER (left). There are
three signaling pathways (IRE1, PERK and ATF6 for detail see text)
for UPR that become activated under conditions of cell stress,
following dysregulation of cell calcium and accumulation of
misfolded or mutant disease-causing proteins such as a-synuclein
(a-syn) in the ER (right). Initially the activated UPR signaling is
neuroprotective, but prolonged UPR causes ER stress that leads to
activation of cell death pathways. MANF as a novel neurotrophic
factor in the ER, reduces ER stress and can restore homeostasis and
counteract cell death. The precise mechanisms by which a-syn
induces ER stress and the action of MANF in cells are under
investigations
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Mitochondria as therapeutic targets in PD
Mitochondria are power plants producing cellular energy in
the form of ATP. These organelles have also important
functions in the regulation of cell metabolism, intracellular
calcium levels and the intrinsic (mitochondria-dependent)
pathway for cell death [40]. Mitochondrial dysfunctions
have been linked to the pathogenesis of PD and manifest
themselves as an increase in oxidative stress, production of
reactive oxygen species (ROS), decreases in OXPHOS
(such as complex I) proteins, mutations in mitochondrial
DNA, an altered mitochondrial dynamics [3–5]. As shown
in familial form of PD by mutations in the PARK genes,
Parkin and PINK disturbances in mitochondrial quality
control mechanisms and selective autophagy (mitophagy)
are important components of the disease [1, 2, 41]. As
recently reviewed [42], neuroprotective strategies to target
mitochondria in PD have proven to be difficult with many
compounds failing in clinical trials, however, other
attempts are currently under scrutiny.
Peroxisome proliferator-activated receptor-c (PPARc)
coactivator-1a (PGC-1a) is a master regulator of mito-
chondrial biogenesis and of genes involved in cell defense
against oxidative stress [43–45]. As shown in PGC-1a gene
deleted mice, brain neurons are more vulnerable to
oxidative stress, while overexpression of PGC-1a can be
neuroprotective in animal models of PD [45, 46]. A recent
meta-analysis of changes observed in postmortem human
PD samples identified PGC-1a as a potential target for
disease intervention [47]. However, the mere overexpres-
sion of PGC-1a may be toxic and increase the vulnerability
of dopaminergic neurons towards oxidative stress linked to
an enhanced mitochondria metabolism [7, 48, 49]. The
fine-tuned regulation of endogenous PGC-1a in neurons by
trophic substances and drugs may therefore be a better
strategy to pursue [50]. Recent studies have shown that
PGC-1a exists in different isoforms in tissues including
brain but the significance of these in PD remains open [51].
PPARc and PGC-1a signaling are altered also in other
human degenerative diseases such as type-2 diabetes
(T2D). Drugs acting on PPARc such as the thiazolidone-
diones (glitazones), rosiglitazone and pioglitazone, which
are commonly used in the treatment of T2D, may have
potentials also for the treatment of PD [52, 53]. Results of
preclinical studies showed that rosiglitazone protects
dopaminergic neurons in animal models of PD, and
pioglitazone can improve parkinsonian syndrome in rhesus
monkeys [54–56]. The beneficial effects of these drugs
were associated with a reduced neuroinflammation and
lower levels of pro-inflammatory cytokines produced by
microglia cells in the brain [55, 56]. A recent epidemio-
logical study on people with T2D revealed a lower
incidence of PD in patients on glitazone drugs [57].
However, a double blind clinical trial in early PD patients
failed to show any improvement of the disease outcome
using pioglitazone [58]. These findings are in contrast to
previous positive data in preclinical studies raising con-
cerns about how well toxin-induced animal models may
recapitulate the course of human PD (see below).
In addition to glitazones, T2D drugs acting through the
glucagon-like peptide R1 receptor (GLP-1R) system have
been shown to be neuroprotective in PD models as well as
in other brain diseases [52, 53, 59]. Most encouragingly, a
clinical trial with exenatide, a GLP-1R agonist, given for
12 months to PD patients, showed that the drug favourably
influenced motor and cognitive functions of patients with
moderate disease [60]. The positive effects of the drug
were sustained in the patients even after a period of
12 months not receiving the drug suggesting a disease-
modifying action of exenatide in PD [61]. A confounding
factor in the study was the lack of proper placebo controls,
and additional clinical trails are required to corroborate the
results [61].
Exenatide and other GLP-1R agonist are well tolerated
in humans as shown in treatment of T2D [52, 53]. Future
trials in PD (Table 2) may benefit from the development of
long-acting GLP-1R agonists and other novel pharmaco-
logical compounds targeting the GLP-1R signaling system
in T2D. It is also important to study the mechanisms of
action of GLP-1R agonist in PD and in neuronal cells as
these may partly differ from those in non-neuronal cells. It
is possible that in the future a multi-therapy using GLP-1R
agonist drugs and trophic factors can provide additional
benefits in the treatment of PD.
Neuroinflammation and oxidative stress in PD
Neuroinflammation with the activation of glial cells has for
long time been linked to the disease pathology in PD [62–
64]. Microglia secrete a number of molecules and the pro-
inflammatory cytokines, interleukin-1b, interferon-c and
tumor necrosis factor alpha (TNFa) as well as nitric oxide
(NO) which all can aggravate the disease. Targeting
microglia activation and the pro-inflammatory cytokines
using drugs or neuroprotective substances is therefore a
valid path to consider for therapy. The neuropeptide
PACAP displays an immunomodulatory effect in the brain,
and some neurotrophic factors may also target microglial
cells (Fig. 2). However, the situation is complex and during
early stages of brain diseases microglia may actually pro-
vide neuroprotection by producing factors such as
interleukin-4 (IL-4) and IL-10. It has been suggested that
microglia cells are of two types, M1 and M2 cells that play
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opposite roles in neuroinflammation depending on the state
of activation and the molecules secreted [65]. Previous
studies in cell culture and in toxin models of PD provided
evidence that IL-10 is protective in dopaminergic neurons,
but so far no clinical investigations have been performed
[66]. Studies of the interplay between different cytokines
and the neuron–glia interactions in the course of PD war-
rant further studies. The role and plasticity of microglial
cells in neuroinflammation have been recently reviewed
[67].
Oxidative stress is a major culprit in PD and linked to
mitochondrial production of ROS and insufficient antioxi-
dant levels in dopaminergic neurons. Studies using
antioxidants such as use of the vitamin E has not shown
promising results in PD. Recent findings indicate that
neuron–astrocyte cross talk plays an important role in the
protection of dopaminergic neurons by induction of an
antioxidant response in astrocytes via activation of the
Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway
[68]. Nrf2 is a transcription factor involved in oxidative
stress and it increased the expression of various antioxi-
dants in the cell. Epidemiologic studies had shown that the
risk of developing PD was lower and the disease progresses
slower in people with higher levels of urate in the blood
[69]. Increasing urate levels would therefore possibly offer
a novel treatment strategy in PD [70]. As a proof-of-prin-
ciple, a study supplementing PD patients with inosine that
can be converted into urate during metabolism was found
to increase urate levels significantly without any adverse
effects [71]. Interestingly, the higher urate levels slowed
Fig. 2 Neurotrophic approaches and cellular pathways in PD.
Pathophysiological events leading to PD are complex and involve
several cellular pathways associated with the disease progression as
depicted here. L-dopa is used for treatment of PD to restore levels of
dopamine in the brain but leads to severe dyskinesia by time. PD is
characterized by the presence of cytoplasmic inclusions called Lewy
body and Lewy neurites (shown as red circles) that contain ubiquitin
and misfolded a-synuclein (a-syn) (black rectangles). Currents drugs
and disease-modifying substances launched for neuroprotection in PD
may act through one or several cellular pathways. Depicted here are
the drugs that target dopaminergic neuron firing and calcium influx
(isradipine), mitochondria (shown in green) and cell metabolism
(glitatzone, GLP-1R agonists), ER stress and inflammatory responses
(different drugs, neuropeptides). The neuropeptide Pacap influences
cell signaling pathways to increase survival and counteract cell
degeneration in neurons. The novel neurotrophic factor, CDNF is both
neuroprotective and neurorestorative in animal models of PD. PDGF-
BB is able to stimulate neurogenesis and favourably influence
dopaminergic neurons, and is well tolerated in PD patients (see text).
The GLP-1R agonists used in treatment of type-2 diabetes have
potentials as disease-modifying drugs in PD but better controlled
clinical trials are required to confirm data. Elevation of urate
concentrations in brain can be neuroprotective via activation of
antioxidant pathways through astrocytes (see text). a-syn a-synuclein,
CDNF cerebral dopamine neurotrophic factor, ER endoplasmic
reticulum, GDNF glial cell line-derived neurotrophic factor, GLI
glitazone, GLP-1R glucagon-like peptide R1 receptor, ISA isradipine,
PACAP pituitary adenylate cyclase-activating polypeptide, PD
Parkinson’s disease, PDGF-BB platelet-derived growth factor BB
isoform
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clinical progression in PD more clearly in women PD
patients than in men [72]. A similar sex difference
regarding urate levels and clinical outcome was observed
in stroke patients [73], and this needs to be taken into
account in further trials using uric acid therapies. Currently
a phase 3 clinical trial using inosine to elevate urate in PD
is planned to answer pertinent questionswhether the treat-
ment can afford neuroprotection and slow disease
progression in PD.
Neurotrophic factors in Parkinson’s disease
GDNF family ligands
GDNF was discovered by its ability to promote the survival
and morphological differentiation of dopaminergic neurons
and to increase their high-affinity dopamine uptake [74].
GDNF and related growth factor, neurturin (NRTN), arte-
min and persephin are homodimeric proteins that form a
distant group of neurotrophic factors in the transforming
growth factor b (TGF-b) superfamily [75]. GDNF acts by
binding specifically to the GPI-anchored GDNF family
receptor alpha 1 (GFRa1) and then this complex interacts
with and activates the receptor tyrosine kinase RET. NRTN
primarily binds to its co-receptor GFRa2, but can activate
RET also via GFRa1 [75, 76]. GDNF and NRTN have also
alternative receptors NCAM and syndecan-3, but their role
for dopamine neurons remains unclear [75, 76].
Studies on gene-deleted animals revealed that GDNF,
GFRa1 as well as RET knockout mice die after birth due to
the lack of kidney, but have an intact nigrastriatal
dopaminergic system, suggesting that GDNF is not crucial
for the development of the dopaminergic neurons [75].
Conditional deletions of GDNF, however, have produced
conflicting results. Thus one study reported a loss of
dopamine neurons [77], whereas the more recent study
using three different GDNF deletion approaches found no
loss of dopamine neurons in adult midbrain [78]. RET
conditional deletion revealed a small loss of midbrain
dopamine neurons in aging mice demonstrating that the
RET signaling is important for the adult maintenance of
these neurons [79].
Preclinical studies have shown that GDNF and NRTN
can promote the survival of dopamine neurons in culture as
well as protect dopamine neurons in rodent and non-human
primate neurotoxin models of PD [76, 80, 81]. Since
GDNF is the mostly used neurotrophic factor in animal
models of PD, it is often considered as the golden standard
for testing other proteins. Experiments using NRTN are
fewer, but NRTN was shown to be effective in most of the
PD animal models studied [76, 80, 81]. The main differ-
ence between GDNF and NRTN is that they use a different
GFRa receptor and that GDNF diffuses better than NRTN
in the brain. However, it is clear that GDNF does not
exhibit a robust protective effect in all models of PD. Thus,
in the severe 6-OHDA model of PD GDNF showed only
modest effects, and GDNF also failed to rescue dopamine
neurons after overexpression of a-syn [76, 81]. This latter
may be due to the fact that increased levels of a-syn can
downregulate the transcription factor Nurr1 leading to a
reduced expression of RET [81] that is required for GDNF
signaling (see above).
GDNF has been tested in two phase 2 trials on PD
patients [76, 82]. In the first trial, GDNF protein was
delivered intracerebroventricularly and the treatment had
no beneficial effects for the patients [76, 83]. However,
GDNF was effective when it was delivered to the caudate
putamen in the phase 1 study [84], and thereafter a second
phase 2 trial with GDNF protein was conducted. In this
trial GDNF was continuously infused to the caudate puta-
men, but again no clinical benefit was observed as
compared to placebo-treated patients [85]. Although, these
pioneering studies were less encouraging they gave valu-
able information and highlighted the importance of basic
research to understand the mechanisms for GDNF action in
aging brain. Currently, two phases 2 trials with GDNF are
ongoing, which partly use a new technology for GDNF
protein delivery. Likewise, a GDNF gene therapy phase 1
trial is on its way and during the coming year we should
hear exciting news about the results of these trials
(Table 2).
Gene therapy has also been used to deliver NTRN to
brains of PD patients in two phase 2 trials. Thus, in a
clinical trial with 58 PD patients receiving adeno-associ-
ated virus serotype 2 expressing NRTN the clinical benefit
was statistically significant but modest, and only after
1 year of treatment [82, 86]. Autopsy data demonstrated
that at least one reason for the modest efficacy could be the
poor diffusion of NRTN in brain tissue. In a second study,
the NRTN-expressing virus was then injected both into the
caudate putamen and substantia nigra. Although, this trial
did not show a statistically significant benefit overall, it
demonstrated efficacy in a small group of patients with
early stage PD [82]. This is encouraging and future studies
using NRTN and GDNF will benefit from better protein
and gene delivery techniques, use of regulated gene therapy
vectors, as well as improving the clinical design, and the
selection of patient groups for treatment.
CDNF and MANF are novel endoplasmic reticulum
located neurotrophic factors for PD
The moderate effects obtained with GDNF and NRTN in
clinical trials have stimulated the search for new growth
factors for PD. In 2003, a protein called mesencephalic
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astrocyte-derived neurotrophic factor (MANF) was char-
acterized and demonstrated to promote the survival of
embryonic dopamine neurons in culture [87]. Subse-
quently, a homologous protein called cerebral dopamine
neurotrophic factor (CDNF) was discovered and found to
be protective for dopamine neurons [88]. CDNF and
MANF proteins differ from other neurotrophic factors in
amino acid sequence and in 3-dimensional structure, and
the proteins are mostly located in the ER [87–89].
Although, the receptors and intracellular signaling path-
ways triggered by CDNF and MANF are still unknown, it
is clear that these factors have a dual mode of action [88,
89]. They can function in the ER interacting with GRP78
and regulating ER stress (Fig. 1), as shown in MANF
knockout mice that have chronically active UPR pathways
[90]. CDNF was also able to protect dopaminergic neurons
against the injury caused by a-syn oligomers [91] which
induces ER stress (Fig. 1).
In addition to their functions in the ER, CDNF and
MANF also act as classical neurotrophic factors on cells by
stimulating still unknown plasma membrane receptors and
intracellular signaling pathways to protect neurons. Thus, it
was shown that CDNF is able to efficiently protect and
repair dopamine neurons in rodent 6-OHDA and MPTP
models of PD [88, 92], while MANF has so far been tested
only in rats using 6-OHDA with beneficial effects [92].
CDNF and MANF diffuse significantly better than GDNF
in brain tissue and in the severe rat 6-OHDA model of PD,
and CDNF was more efficient than GDNF [93]. Moreover,
recent experiments in rhesus monkey using MPTP as a
toxin for dopaminergic neurons demonstrated that CDNF is
effective in protecting and repairing these neurons by
preventing their degeneration and death (unpublished data).
CDNF was also shown to improve motor behavior of
rhesus monkeys and currently clinical trials with CDNF in
PD patients have been planned in 2016.
Taken together CDNF and MANF are new growth
factors that are ER-resident protein that may be secreted
under certain conditions such as after injury. These factors
can protect injured neurons extracellularly by interacting
with plasma membrane receptors and by acting inside the
cells also modulate UPR and ER stress that contributes to
the maintenance and functioning of dopamine neurons.
Other growth factors with neuroprotective
potentials in PD
In addition to GDNF and CDNF-MANF family proteins,
many growth factors can protect dopamine neurons in
animal models of PD when injected into the brain before
the neurotoxin lesion. However, in a clinically more rele-
vant neurorestorative model, when animals are first
lesioned with the neurotoxin and only then treated with
growth factor, very few factors show neurorestorative
activity. Among the proteins that have shown some pro-
tective effects after the toxin-induced lesion, one should
mention, VEGF-A, VEGF-B, PDGF-BB and some mem-
bers of the FGF family (see below). VEGF-A enhances the
survival of embryonic midbrain dopaminergic neurons
in vitro, and is both neuroprotective and neurorestorative in
the 6-OHDA rat model of PD [94]. In addition, VEGF-B
can stimulate neurogenesis, promote the survival of cul-
tured dopaminergic neurons and protect against 6-OHDA
injuries in the rat [94]. Also VEGF-C acts directly on
dopamine neurons promoting the survival in vitro and
in vivo. However, the in vivo effects of VEGF-C in
6-OHDA animal models of PD were rather modest [94].
Future therapies may include simultaneous use of sev-
eral growth factors. One very exciting example is the
collaboration of GDNF with TGF-b. Thus, it has been
shown that the neurotrophic effect of GDNF in vitro and
in vivo requires the presence of TGF-b [95]. TGF-b
induced recruitment of the GDNF receptor, GFRa1 to the
plasma membrane, thereby permitting GDNF signaling and
neurotrophic effects. The combined effect of GDNF-TGF-
b is robust in rodent models of PD but the efficacy of this
has not yet been examined in non-human primates [95].
PDGF
Platelet-derived growth factor (PDGF) has multitude of
functions in different organs including stimulation of cell
proliferation [96]. Biologically active PDGF is a dimer that
binds to specific tyrosine kinase PDGF receptors on target
cells [96]. Different isoforms of PDGF exist in tissues, and
the PDGF-BB isoform was shown to be protective in cul-
tured dopaminergic neurons [97]. PDGF-BB was also
increased in brain after treatment with 6-OHDA suggesting
a compensatory response [98]. Along this line, PDGF-BB
injections induced functional recovery and provided neu-
roprotection of the lesioned nigrastriatal system [99]. Data
showed that PDGF-BB might act not directly on
dopaminergic neurons, but on neural progenitor and stem
cells in the subventricular zone to enhance neurogenesis
[99]. Together these results raised the possibility that
stimulation of neurogenesis in the brain can enhance
recovery and possibly halt the process of cell degeneration
in PD. A pilot study with 12 PD patients further showed
that administration of PDGF-BB into the brain ventricles
for 2 weeks was well tolerated with no obvious side effects
[100]. The design of this first trial (the short treatment
period, few patients enrolled) was not designed to evaluate
the clinical efficacy of PDGF-BB. However, an increase in
dopamine transporter (DAT) binding was noted in the
putamen of PDGF-BB-treated patient group [100]. Further,
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clinical trials with PD patients are planned (Table 2) to
study relevant questions concerning the efficacy, responses
and neuroprotective potentials of PDGF-BB in PD [101].
Given PDGF-BB‘s unique action to stimulate neurogenesis
it may be possible to consider a co-treatment with PDGF-
BB and other trophic factors or drugs to restore the
nigrostriatal system and provide neuroprotection in PD
(Fig. 2).
Fibroblast growth factor (FGF) family
Members of the fibroblast growth factor (FGF) family are
secreted proteins that signal via activation of their cognate
receptors, consisting of four transmembrane FGF-receptor
tyrosine kinases (FGFR1-4). The FGFs have diverse
functions ranging from tissue development to metabolism,
and some members are also known to display trophic
actions on dopaminergic neurons. Thus, FGF20 showed
neuroprotection in vitro [102, 103], and attenuated
dopaminergic neuron loss and improve behavior in the rat
6-OHDA toxin model of PD [104].
FGF20 can also generate a large number of dopamin-
ergic neurons from different sources of stem cells,
including human embryonic stem cells, making it an useful
factor for cell-based therapies in PD [105]. There are also
reports showing polymorphisms in the regulatory region of
the FGF20 gene in PD [106]. However, other studies have
reported that FGF20 is probably not a risk factor for PD
[107].
In addition to FGF20, several studies have shown that
FGF2 can exert protective effects on cultured as well as on
midbrain dopaminergic neurons in vivo, and these results
have been reviewed [108]. Data thus support a therapeutic
potential of FGF20 and FGF2 in PD, but pre-clinical trials
have been hampered by the rapid plasma clearance,
molecular instability and poor permeability of these factors
through the blood–brain barrier.
FGF21
Fibroblast growth factor 21 (FGF21) is an endocrine
growth factor that influences glucose and lipid metabo-
lism in the body [109, 110]. FGF21 acts on targets cells
by activating the FGF receptor tyrosine kinase in con-
junction with the cofactor b-klotho [111]. Elevated serum
levels of FGF21 are linked to mitochondrial diseases in
humans [112]. The biology of FGF21 is complex and the
factor can have both systemic and local effects in tissues
[109]. FGF21 can pass the blood–brain barrier [113] and
may display a good penetration in brain tissue as its
lacks the heparin-binding domain present in classical
FGFs [109]. FGF21 is able to extend life span in mice
[114], suggesting that it may have beneficial effects on
the aging process associated with cell degeneration.
Recently, it was shown that FGF21 stimulates mito-
chondrial functions and PGC-1a signaling in human
dopaminergic neurons [115]. The potential role of FGF21
in regulation of the viability of aging dopaminergic
neurons and in models of PD warrants further
investigations.
Pituitary adenylate cyclase-activating polypeptide
(PACAP)
PACAP is a member of the secretin/glucagon superfamily
[116], and shown to have multiple effects in different tis-
sues, including brain [117–119]. PACAP acts via
G-protein-coupled receptors, named PAC1R (specific for
PACAP) and the VPAC1 and VPAC2 receptors (shared
with the peptide VIP [120]. PACR1 is widely expressed by
neurons in the brain including the dopaminergic neurons.
PACAP activates both the cAMP/protein kinase A and the
phospholipase C/protein kinase C (PKC) pathways
depending on the expression of different PAC1R isoforms
[118–120]. The mechanism by which PACAP enhances
neuroprotection is complex but related to an increase in
specific genes and pathways regulated by cAMP and/or
calcium in the neurons [121, 122]. It has also been shown
that there is cross talk between PACAP and neurotrophic
factor signaling in neurons [123] and this may add to cell
protection.
Accumulating evidences support the view that PACAP
is neuroprotective on dopaminergic neurons as shown in
cell culture experiments [124, 125] and in vivo PD models
using the neurotoxins, 6-OHDA and MPTP [126].
Dopaminergic neurons in PACAP-deficient mice are also
more susceptible to the toxin paraquat and show changes in
microglia and immune responses [127].
PACAP has also a strong anti-inflammatory action, and
the peptide can counteract the effects of pro-inflammatory
cytokines produced by microglia cells [128, 129]. PACAP
is able to cross the blood–brain barrier [130, 131], but the
peptide has a short half-life in tissues due to proteolysis. As
to possible treatments PACR1 agonists like maxadilan or
fragments or derivate of PACAP may therefore be more
useful [119, 122]. In view of the many targets, adminis-
tration of PACAP may produce side effects that may
preclude a long-term treatment with the peptide. For future
therapies involving PACAP, it is therefore necessary to
carefully consider issues of safety, doses, pharmacological
profile, kinetics and the mode of administration of the
peptide.
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Clinical trials in PD
Figure 2 shows a brief summary of recent disease-modi-
fying agents and their known or inferred mechanism of
action in PD. Several molecules and trophic factors
showing promising neuroprotective actions in preclinical
experiments have failed to do so in rigorous clinical trials.
These outcomes have been the subject of a recent review
[28]. It is foreseen that an increased understanding of
mechanisms underlying PD together with the development
of better animal models reflecting the complexity of human
PD can help to reveal novel targets for intervention.
Regarding trophic factors, treatments with GDNF or
NRTN have produced mixed results raising questions about
doses, methods of delivery and tissue penetration of the
factors. The possible beneficial role of GDNF in PD is
being further explored (Table 2). The novel dopaminergic
factor CDNF showed positive results in preclinical models
of PD, and CDNF is currently studied in rhesus monkey PD
model and entering clinical trials. The first experiments
with PDGF-BB infused to human brains showed a good
tolerability in PD patients encouraging further clinical tri-
als using this growth factor (Table 2). GLP-1 agonists
primarily used for the treatment of T2D have also shown
beneficial effects in preclinical models of PD. Recently, an
open-label clinical study using exenatide revealed a sus-
tained positive effect in PD patients with improvement of
clinical scoring suggesting a disease-modifying effect of
the drug (Table 2). Currently, further studies are underway
to confirm these results using exenatide and also other
GLP-1 agonists in PD. At the same time, more preclinical
work is required to better understand the mechanisms of
action of these compounds in providing neuroprotection
and promote functional recovery in PD patients. In addition
to drugs and growth factors immunotherapies targeting a-
syn may show potential benefits in the disease, but this has
to await the first clinical trial with PD patients (Table 2).
Conclusions and future prospective
PD has a complex etiology with contributions of genetic
and environmental risk factors. Patients afflicted by the
disease show both motor and non-motor symptoms and the
current treatments with dopamine replacement using
L-dopa and other dopamine agonists target mainly the
former. No drugs or therapies are currently available to
efficiently target the neurodegenerative process or slow
disease progression in PD. Recent studies on the patho-
physiology and genetic causes of PD have raised hopes that
it may be possible in the future to design and tailor-made
disease-modifying therapies and neuroprotective agents in
PD. However to accomplish this more preclinical work into
the mechanisms of neuroprotection is required combined
with controlled and well-designed clinical trials of
promising drugs and disease-modifying substances in PD
patients. Studies on-going to identify novel biomarkers for
PD are also important (see www.clinicaltrials.gov) and will
be helpful for early diagnosis and for treatment, and for
follow-up of outcomes of clinical trials in PD. For effective
therapies, the stratification of PD patient according to eti-
ology (familial and sporadic forms) is also crucial as these
may vary between patient groups. Depending on the
severity and state of the disease, PD patients may require a
different treatment approach for example with regard to
targeting neuroinflammation that depending on the func-
tional state of microglia may be a friend or a foe in the
disease. It is also possible that not one single but a com-
bined therapy is required to effectively combat cell
degeneration and restore neuronal functions in PD. The
current research on neuroprotective agents and disease-
modifying drugs in PD has generated promising data that
bears potentials for a better treatment of patients afflicted
by this dreadful disease.
Acknowledgments The work in the groups is supported by Acad-
emy of Finland (DL, MS), Jane and Aatos Erkko Foundation (MS),
Michael J Fox Foundation for Parkinson’s Research (MS), Finnish
Parkinson Foundation (DL, JM), Minerva Foundation (DL, JM),
University of Helsinki (DL, JM, OE, MS) and by Progetti di Ateneo,
University of Palermo (VD, GM, NB).
References
1. Klein C, Westenberger A (2012) Genetics of Parkinson’s dis-
ease. Cold Spring Harb Perspect Med. 2:a008888
2. Mullin S, Schapira A (2015) The genetics of Parkinson’s dis-
ease. Br Med Bull 114:39–52
3. Henchcliffe C, Beal MF (2008) Mitochondrial biology and
oxidative stress in Parkinson disease pathogenesis. Nat Clin
Pract Neurol 4:600–609
4. Gupta A, Dawson VL, Dawson TM (2008) What causes cell
death in Parkinson’s disease? Ann Neurol 64(Suppl 2):S3–S15
5. Perier C, Vila M (2012) Mitochondrial biology and Parkinson’s
disease. Cold Spring Harb Perspect Med 2:a009332
6. Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic
E, Schumacker PT, Surmeier DJ (2010) Oxidant stress evoked
by pacemaking in dopaminergic neurons is attenuated by DJ-1.
Nature 468:696–700
7. Pacelli C, Giguere N, Bourque M-J, Le´vesque M, Slack RS,
Trudeau LE (2015) Elevated mitochondrial mioenergetics and
axonal arborization size are key contributors to the vulnerability
of dopamine neurons. Curr Biol 25:2349–2360. doi:10.1016/j.
cub.2015.07.050
8. Goedert M, Spillantini MG, Del Tredici K, Braak H (2013)
100 years of Lewy pathology. Nat Rev Neurol 9:13–24
9. Brundin P, Atkin G, Lamberts JT (2015) Basic science breaks
through: new therapeutic advances in Parkinson’s disease. Mov
Disord 30:1521–1527. doi:10.1002/mds.26332
Current disease modifying approaches to treat Parkinson’s disease 1375
123
10. Betzer C, Movius AJ, Shi M, Gai WP, Zhang J, Jensen PH
(2015) Identification of synaptosomal proteins binding to
monomeric and oligomeric a-synuclein. PLoS One 10:e0116473
11. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D
(2004) Impaired degradation of mutant alpha-synuclein by
chaperone-mediated autophagy. Science 305:1292–1295
12. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH
(2009) Alterations in lysosomal and proteasomal markers in
Parkinson’s disease: relationship to alpha-synuclein inclusions.
Neurobiol Dis 35:385–398
13. Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J,
Bjo¨rklund A (2013) TFEB-mediated autophagy rescues mid-
brain dopamine neurons from a-synuclein toxicity. Proc Natl
Acad Sci U S A 110:E1817–E1826
14. Schapira AH (2015) Glucocerebrosidase and Parkinson disease:
recent advances. Mol Cell Neurosci 66:37–42
15. Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW,
Schapira AH (2012) Glucocerebrosidase deficiency in substantia
nigra of parkinson disease brains. Ann Neurol 72:455–463
16. Gegg ME, Sweet L, Wang BH, Shihabuddin LS, Sardi SP,
Schapira AH (2015) No evidence for substrate accumulation in
Parkinson brains with GBA mutations. Mov Disord
30:1085–1089
17. Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ,
Kolodziej P, Kahn I, Saftig P, Woulfe J, Rochet JC, Glicksman
MA, Cheng SH, Grabowski GA, Shihabuddin LS, Schloss-
macher MG (2011) Acid b-glucosidase mutants linked to
Gaucher disease, Parkinson disease, and Lewy body dementia
alter a-synuclein processing. Ann Neurol 69:940–953
18. Braak H, Del Tredici K, Ru¨b U, de Vos RA, Jansen Steur EN,
Braak E (2003) Staging of brain pathology related to sporadic
Parkinson’s disease. Neurobiol Aging 24:197–211
19. Braak H, Bohl JR, Mu¨ller CM, Ru¨b U, de Vos RA, Del Tredici
K (2006) Stanley Fahn Lecture 2005: the staging procedure for
the inclusion body pathology associated with sporadic Parkin-
son’s disease reconsidered. Mov Disord 21:2042–2051
20. Dehay B, Vila M, Bezard E, Brundin P, Kordower JH (2015)
Alpha-synuclein propagation: New insights from animal models.
Mov Disord. doi:10.1002/mds.26370
21. Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L,
Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja
M, Kinnunen E, Murros K, Auvinen P (2015) Gut microbiota are
related to Parkinson’s disease and clinical phenotype. Mov
Disord 30:350–358
22. Schapira AH, Olanow CW, Greenamyre JT, Bezard E (2014)
Slowing of neurodegeneration in Parkinson’s disease and
Huntington’s disease: future therapeutic perspectives. Lancet
384:545–555
23. Lindstro¨m V, Ihse E, Fagerqvist T, Bergstro¨m J, Nordstro¨m E,
Mo¨ller C, Lannfelt L, Ingelsson M (2014) Immunotherapy tar-
geting a-synuclein, with relevance for future treatment of
Parkinson’s disease and other Lewy body disorders.
Immunotherapy 6:141–153
24. Walter P, Ron D (2011) The unfolded protein response: from
stress pathway to homeostatic regulation. Science
334:1081–1086
25. Lindholm D, Wootz H, Korhonen L (2006) ER stress and neu-
rodegenerative diseases. Cell Death Differ 13:385–392
26. Hetz C, Mollereau B (2014) Disturbance of endoplasmic retic-
ulum proteostasis in neurodegenerative diseases. Nat Rev
Neurosci 15:233–249
27. Ryu EJ, Harding HP, Angelastro JM, Vitolo OV, Ron D, Greene
LA (2002) Endoplasmic reticulum stress and the unfolded pro-
tein response in cellular models of Parkinson’s disease.
J Neurosci 22:10690–10698
28. Baek JH, Whitfield D, Howlett D, Francis P, Bereczki E, Ballard
C, Hortoba´gyi T, Attems J, Aarsland D (2015) Unfolded protein
response is activated in Lewy body dementias. Neuropathol
Appl Neurobiol. doi:10.1111/nan.12260
29. Chung CY, Khurana V, Auluck PK, Tardiff DF, Mazzulli JR,
Soldner F, Baru V, Lou Y, Freyzon Y, Cho S, Mungenast AE,
Muffat J, Mitalipova M, Pluth MD, Jui NT, Schu¨le B, Lippard
SJ, Tsai LH, Krainc D, Buchwald SL, Jaenisch R, Lindquist S
(2013) Identification and rescue of a-synuclein toxicity in
Parkinson patient-derived neurons. Science 342:983–987
30. Mercado G, Valde´s P, Hetz C (2013) An ERcentric view of
Parkinson’s disease. Trends Mol Med 19:165–715
31. Mercado G, Castillo V, Vidal R, Hetz C (2015) ER proteostasis
disturbances in Parkinson’s disease: novel insights. Front Aging
Neurosci. 7:39
32. Imai Y, Takahashi R (2004) How do Parkin mutations result in
neurodegeneration? Curr Opin Neurobiol 14:384–389
33. Kitao Y, Imai Y, Ozawa K, Kataoka A, Ikeda T, Soda M,
Nakimawa K, Kiyama H, Stern DM, Hori O, Wakamatsu K, Ito
S, Itohara S, Takahashi R, Ogawa S (2007) Pael receptor
induces death of dopaminergic neurons in the substantia nigra
via endoplasmic reticulum stress and dopamine toxicity, which
is enhanced under condition of parkin inactivation. Hum Mol
Genet 16:50–60
34. Thayanidhi N, Helm JR, Nycz DC, Bentley M, Liang Y, Hay JC
(2010) Alpha-synuclein delays endoplasmic reticulum (ER)-to-
Golgi transport in mammalian cells by antagonizing ER/Golgi
SNAREs. Mol Biol Cell 21:1850–1863
35. Colla E, Coune P, Liu Y, Pletnikova O, Troncoso JC, Iwatsubo
T, Schneider BL, Lee MK (2012) Endoplasmic reticulum stress
is important for the manifestations of a-synucleinopathy in vivo.
J Neurosci 32:3306–3320
36. Hayashi T, Rizzuto R, Hajnoczky G, Su TP (2009) MAM: more
than just a housekeeper. Trends Cell Biol 19:81–88
37. Guardia-Laguarta C, Area-Gomez E, Ru¨b C, Liu Y, Magrane´ J,
Becker D, Voos W, Schon EA, Przedborski S (2014) a-Synu-
clein is localized to mitochondria-associated ER membranes.
J Neurosci 34:249–259
38. Francardo V, Bez F, Wieloch T, Nissbrandt H, Ruscher K, Cenci
MA (2014) Pharmacological stimulation of sigma-1 receptors
has neurorestorative effects in experimental parkinsonism. Brain
137:1998–2014
39. Hyrskyluoto A, Pulli I, To¨rnqvist K, Ho TH, Korhonen L,
Lindholm D (2013) Sigma-1 receptor agonist PRE084 is pro-
tective against mutant huntingtin-induced cell degeneration:
involvement of calpastatin and the NF-jB pathway. Cell Death
Dis 4:e646
40. Nunnari J, Suomalainen A (2012) Mitochondria: in sickness and
in health. Cell 148:1145–1159
41. Rugarli EI, Langer T (2012) Mitochondrial quality control: a
matter of life and death for neurons. EMBO J 31:1336–1349
42. Kalia LV, Kalia SK, Lang AE (2015) Disease-modifying
strategies for Parkinson’s disease. Mov Disord. doi:10.1002/
mds.26354
43. Puigserver P, Spiegelman BM (2003) Peroxisome proliferator-
activated receptor-gamma coactivator 1 alpha (PGC-1 alpha):
transcriptional coactivator and metabolic regulator. Endocr Rev
24:78–90
44. Houten SM, Auwerx J (2004) PGC-1alpha: turbocharging
mitochondria. Cell 119:5–7
45. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Ja¨ger S,
Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R,
Spiegelman BM (2006) Suppression of reactive oxygen species
and neurodegeneration by the PGC-1 transcriptional coactiva-
tors. Cell 127:397–408
1376 D. Lindholm et al.
123
46. Mudo` G, Ma¨kela¨ J, Di Liberto V, Tselykh TV, Olivieri M,
Piepponen P, Eriksson O, Ma¨lkia¨ A, Bonomo A, Kairisalo M,
Aguirre JA, Korhonen L, Belluardo N, Lindholm D (2012)
Transgenic expression and activation of PGC-1a protect
dopaminergic neurons in the MPTP mouse model of Parkinson’s
disease. Cell Mol Life Sci 69:1153–1165
47. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt
ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA,
Gru¨nblatt E, Moran LB, Mandel SA, Riederer P, Miller RM,
Federoff HJ, Wu¨llner U, Papapetropoulos S, Youdim MB,
Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen
JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet
JC, Scherzer CR, Global PD Gene Expression (GPEX) Con-
sortium (2010) PGC-1a, a potential therapeutic target for early
intervention in Parkinson’s disease. Sci Transl Med 2: 52ra73
48. Ciron C, Lengacher S, Dusonchet J, Aebischer P, Schneider BL
(2012) Sustained expression ofPGC-1a in the rat nigrostriatal
system selectively impairs dopaminergic function. Hum Mol
Genet 21:1861–1876
49. Clark J, Silvaggi JM, Kiselak T, Zheng K, Clore EL, DaiY Bass
CE, Simon DK (2012) Pgc-1a overexpression downregulates
Pitx3 and increases susceptibility to MPTP toxicity associated
with decreased Bdnf. PLoS One 7:e48925
50. Lindholm D, Eriksson O, Makela J, Belluardo N, Korhonen L
(2012) PGC-1alpha: a master gene that is hard to master. Cell
Mol Life Sci 69:2465–2468
51. Soyal SM, Felder TK, Auer S, Hahne P, Oberkofler H, Witting
A, Paulmichl M, Landwehrmeyer GB, Weydt P, Patsch W,
Network European Huntington Disease (2012) A greatly
extended PPARGC1A genomic locus encodes several new
brain-specific isoforms and influences Huntington disease age of
onset. Hum Mol Genet 21:3461–3473
52. Aviles-Olmos I, Limousin P, Lees A, Foltynie T (2013)
Parkinson’s disease, insulin resistance and novel agents of
neuroprotection. Brain 136:374–384
53. Patrone C, Eriksson O, Lindholm D (2014) Diabetes drugs and
neurological disorders: new views and therapeutic possibilities.
Lancet Diabetes Endocrinol 2:256–262
54. Schintu N, Frau L, Ibba M, Caboni P, Garau A, Carboni E, Carta
AR (2009) PPAR-gamma-mediated neuroprotection in a chronic
mouse model of Parkinson’s disease. Eur J Neurosci 29:954–963
55. Carta AR, Frau L, Pisanu A, Wardas J, Spiga S, Carboni E
(2011) Rosiglitazone decreases peroxisome proliferator recep-
tor-gamma levels in microglia and inhibits TNF-alpha
production: new evidences on neuroprotection in a progressive
Parkinson’s disease model. Neuroscience 194:250–261
56. Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA,
Ziegler TE, Kemnitz JW, Johnson JA, Emborg ME (2011) The
PPAR-c agonist pioglitazone modulates inflammation and
induces neuroprotection in parkinsonian monkeys. J Neuroin-
flammation 8:91. doi:10.1186/1742-2094-8-91
57. Brauer R, Bhaskaran K, Chaturvedi N, Dexter DT, Smeeth L,
Douglas I (2015) Glitazone treatment and incidence of Parkin-
son’s disease among people with diabetes: a retrospective cohort
study. PLoS Med 12:e1001854
58. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-
ZONE Investigators (2015) Pioglitazone in early Parkinson’s
disease: a phase 2, multicentre, double-blind, randomised trial.
Lancet Neurol 14:795–803
59. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway
HW, Powers K, Shen H, Egan JM, Sambamurti K, Brossi A,
Lahiri DK, Mattson MP, Hoffer BJ, Wang Y, Greig NH (2009)
GLP-1 receptor stimulation preserves primary cortical and
dopaminergic neurons in cellular and rodent models of stroke
and Parkinsonism. Proc Natl Acad Sci USA 106:1285–1290
60. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell
P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin
P, Foltynie T (2013) Exenatide and the treatment of patients
with Parkinson’s disease. J Clin Invest 123:2730–2736
61. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A,
Kahan J, Ell P, Whitton P, Wyse R, Isaacs T, Lees A, Limousin
P, Foltynie T (2014) Motor and cognitive advantages persist
12 months after exenatide exposure in Parkinson’s disease.
J Parkinsons Dis 4:337–344
62. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive
microglia are positive for HLA-DR in the substantia nigra of
Parkinson’s and Alzheimer’s disease brains. Neurology
38:1285–1291
63. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers
A, Eggert K, Oertel W, Banati RB, Brooks DJ (2006) In vivo
imaging of microglial activation with [11C](R)-PK11195 PET
in idiopathic Parkinson’s disease. Neurobiol Dis 21:404–412
64. Ouchi Y, Yagi S, Yokokura M, Sakamoto M (2009) Neuroin-
flammation in the living brain of Parkinson’s disease.
Parkinsonism Relat Disord 15:S200–S204
65. Sica A, Mantovani A (2012) Macrophage plasticity and polar-
ization: in vivo veritas. J Clin Invest. 122:787–795
66. Kwilasz AJ, Grace PM, Serbedzija P, Maier SF, Watkins LR
(2015) The therapeutic potential of interleukin-10 in neuroim-
mune diseases. Neuropharmacology 96:55–69
67. Fernandes A, Miller-Fleming L, Pais TF (2014) Microglia and
inflammation: conspiracy, controversy or control? Cell Mol Life
Sci 71:3969–3985
68. Bakshi R, Zhang H, Logan R, Joshi I, Xu Y, Chen X, Sch-
warzschild MA (2015) Neuroprotective effects of urate are
mediated by augmenting astrocytic glutathione synthesis and
release. Neurobiol Dis. doi:10.1016/j.nbd.2015.08.022
69. Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA,
Ascherio A (2007) Plasma urate and risk of Parkinson’s disease.
Am J Epidemiol 166:561–567
70. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR,
Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR,
Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S,
Shoulson I, Schwarzschild MA, Parkinson Study Group
DATATOP Investigators (2009) Urate as a predictor of the rate
of clinical decline in Parkinson disease. Arch Neurol
66:1460–1468
71. Parkinson Study Group SURE-PD Investigators, Schwarzschild
MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare
JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph
A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A,
Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R,
Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray
M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Gou-
dreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH,
Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Anto-
nelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J,
Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R,
Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S,
Venuto C, Weber J, Eaton K (2014) Inosine to increase serum
and cerebrospinal fluid urate in Parkinson disease: a randomized
clinical trial. JAMA Neurol 71:141–150
72. Schwarzschild MA, Macklin EA, Ascherio A, Parkinson Study
Group SURE-PD Investigators (2014) Urate and neuroprotec-
tion trials. Lancet Neurol 13:758
73. Chamorro A, Amaro S, Castellanos M, Segura T, Arenillas J,
Martı´-Fa´bregas J, Ga´llego J, Krupinski J, Gomis M, Ca´novas D,
Carne´ X, Deulofeu R, Roma´n LS, Oleaga L, Torres F, Planas
AM, Investigators URICO-ICTUS (2014) Safety and efficacy of
uric acid in patients with acute stroke (URICO-ICTUS): a
Current disease modifying approaches to treat Parkinson’s disease 1377
123
randomised, double-blind phase 2b/3 trial. Lancet Neurol
13:453–460
74. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993)
GDNF: a glial cell line-derived neurotrophic factor for midbrain
dopaminergic neurons. Science 260:1130–1132
75. Airaksinen MS, Saarma M (2002) The GDNF family: signalling,
biological functions and therapeutic value. Nat Rev Neurosci
3:383–394
76. Domanskyi A, Saarma M, Airavaara M (2015) Prospects of
neurotrophic factors for Parkinson’s disease: comparison of
protein and gene therapy. Hum Gene Ther 26:550–559
77. Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, Go´mez-
Dı´az R, Lo´pez-Barneo J (2008) Absolute requirement of GDNF
for adult catecholaminergic neuron survival. Nat Neurosci
11:755–761
78. Kopra J, Vilenius C, Grealish S, Harma M-A, Varendi K, Lind-
holm J, Castren E, Voikar V, Bjorklund A, Piepponen TP, Saarma
M, Andressoo J-O (2015) GDNF is not required for cate-
cholaminergic neuron survival in vivo. Nat Neurosci 18:319–322
79. Kramer ER, Aron L, Ramakers GM, Seitz S, Zhuang X, Beyer
K, Smidt MP, Klein R (2007) Absence of Ret signaling in mice
causes progressive and late degeneration of the nigrostriatal
system. PLoS Biol 5:e39
80. Aron L, Klein R (2011) Repairing the parkinsonian brain with
neurotrophic factors. Trends Neurosci 34:88–100
81. Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann
T, Bjo¨rklund A (2012) a-Synuclein-induced down-regulation of
Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci
Transl Med 4:163ra156
82. Bartus RT, Weinberg MS, Samulski RJ (2014) Parkinson’s
disease gene therapy: successby design meets failure by effi-
cacy. Mol Ther 22:487–497
83. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws
ER Jr, Lozano AM, Penn RD, Simpson RK Jr, Stacy M, Wooten
GF; ICV GDNF Study Group (2003) Implanted intracere-
broventricular. Glial cell line-derived neurotrophic factor.
Randomized, double-blind trial of glial cell line-derived neu-
rotrophic factor (GDNF) in PD. Neurology 6:69–73
84. Gill SS, Patel NK, Hotton GR, O’Sullivan K, McCarter R,
Bunnage M, Brooks DJ, Svendsen CN, Heywood P (2003)
Direct brain infusion of glial cell line-derived neurotrophic
factor in Parkinson disease. Nat Med 9:589–595
85. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks
DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K,
Kelly P, Dalvi A, Scott B, Stacy M, Turner D, Wooten VG,
Elias WJ, Laws ER, Dhawan V, Stoessl AJ, Matcham J, Coffey
RJ, Traub M (2006) Randomized controlled trial of intraputa-
menal glial cell line-derived neurotrophic factor infusion in
Parkinson disease. Ann Neurol 59:459–466
86. Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis
N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R,
Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R,
Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J,
Kieburtz K, Kordower JH, Olanow CW (2010) Gene delivery of
AAV2-neurturin for Parkinson’s disease: a double-blind, ran-
domised, controlled trial. Lancet Neurol 9:1164–1172
87. Petrova P, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK,
Peaire AE, Shridhar V, Smith DI, Kelly J, Durocher Y, Com-
missiong JW (2003) MANF: a new mesencephalic, astrocyte-
derived neurotrophic factor with selectivity for dopaminergic
neurons. J Mol Neurosci 20:173–188
88. Lindholm P, Voutilainen MH, Laure´n J, Pera¨nen J, Leppa¨nen
V-M, Andressoo J-O, Lindahl M, Janhunen S, Kalkkinen N,
Timmusk T, Tuominen RK, Saarma M (2007) Novel neu-
rotrophic factor CDNF protects and rescues midbrain
dopaminergic neurons in vivo. Nature 448:73–77
89. Lindholm P, Saarma M (2010) Novel CDNF/MANF family of
neurotrophic factors. Dev Neurobiol 70:360–371
90. Lindahl M, Danilova T, Palm E, Pulkkila P, Voikar V, Hakonen
E, Ustinov J, Andressoo J-O, Harvery B, Otonkoski T, Rossi J,
Saarma M (2014) MANF is indispensable for the proliferation
and survival of pancreatic b-cells. Cell Reports 7:366–375
91. Latge C, Cabral KM, Johanson L, Roma˜o LF, Herrmann T,
Almeida MS, Foguel D (2015) The solution structure and
dynamics of full-length human cerebral dopamine neurotrophic
factor and its neuroprotective role against a-synuclein oligo-
mers. J Biol Chem 290:20527–20540
92. Voutilainen MH, Ba¨ck S, Po¨rsti E, Toppinen L, Lindgren L,
Lindholm P, Pera¨nen J, Saarma M, Tuominen RK (2009)
Mesencephalic astrocyte-derived neurotrophic factor is neu-
rorestorative in rat model of Parkinson’s disease. J Neurosci
29:9651–9659
93. Voutilainen MH, Ba¨ck S, Pera¨nen J, Lindholm P, Raasmaja A,
Ma¨nnisto¨ PT, Saarma M, Tuominen RK (2011) Chronic infusion
of CDNF prevents 6-OHDA-induced deficits in a rat model of
Parkinson’s disease. Exp Neurol 228:99–108
94. Piltonen M, Planken A, Leskela¨ O, Myo¨ha¨nen TT, Ha¨nninen
AL, Auvinen P, Alitalo K, Andressoo JO, Saarma M, Ma¨nnisto¨
PT (2011) Vascular endothelial growth factor C acts as a neu-
rotrophic factor for dopamine neurons in vitro and in vivo.
Neuroscience 192:550–563
95. Peterziel H, Unsicker K, Krieglstein K (2002) TGFbeta induces
GDNF responsiveness in neurons by recruitment of GFRalpha1
to the plasma membrane. J Cell Biol 59:157–167
96. Heldin CH, Westermark B (1999) Mechanism of action and
in vivo role of platelet-derived growth factor. Physiol Rev
79:1283–1316
97. Pietz K, Odin P, Funa K, Lindvall O (1996) Protective effect of
platelet-derived growth factor against 6-hydroxydopamine-in-
duced lesion of rat dopaminergic neurons in culture. Neurosci
Lett 204:101–104
98. Funa K, Yamada N, Brodin G, Pietz K, Ahgren A, Wictorin K,
Lindvall O, Odin P (1996) Enhanced synthesis of platelet-
derived growth factor following injury induced by 6-hydroxy-
dopamine in rat brain. Neuroscience 74:825–833
99. Zachrisson O, Zhao M, Andersson A, Dannaeus K, Ha¨ggblad J,
Isacson R, Nielsen E, Patrone C, Ro¨nnholm H, Wikstrom L,
Delfani K, McCormack AL, Palmer T, Di Monte DA, Hill MP,
Janson Lang AM, Haegerstrand A (2011) Restorative effects of
platelet derived growth factor-BB in rodent models of Parkin-
son’s disease. J Parkinsons Dis 1:49–63
100. Paul G, Zachrisson O, Varrone A, Almqvist P, Jerling M, Lind
G, Rehncrona S, Linderoth B, Bjartmarz H, Shafer LL, Coffey
R, Svensson M, Mercer KJ, Forsberg A, Halldin C, Sven-
ningsson P, Widner H, Frise´n J, Pa˚lhagen S, Haegerstrand A
(2015) Safety and tolerability of intracerebroventricular PDGF-
BB in Parkinson’s disease patients. J Clin Invest.
125:1339–1346
101. Foltynie T (2015) Can Parkinson’s disease be cured by stimu-
lating neurogenesis? J Clin Invest 125:978–980
102. Ohmachi S, Mikami T, Konishi M, Miyake A, Itoh N (2003)
Preferential neurotrophic activity of fibroblast growth factor-20
for dopaminergic neurons through fibroblast growth factor
receptor-1c. J Neurosci Res 72:436–443
103. Murase S, McKay RD (2006) A specific survival response in
dopamine neurons at most risk in Parkinson’s disease. J Neu-
rosci 26:9750–9760
104. Sleeman IJ, Boshoff EL, Duty S (2012) Fibroblast growth fac-
tor-20 protects against dopamine neuron loss in vitro and
provides functional protection in the 6-hydroxydopamine-le-
sioned rat model of Parkinson’s disease. Neuropharmacology
63:1268–1277
1378 D. Lindholm et al.
123
105. Correia AS, Anisimov SV, Li JY, Brundin P (2008) Growth
factors and feeder cells promote differentiation of human
embryonic stem cells into dopaminergic neurons: a novel role
for fibroblast growth factor-20. Front Neurosci 2:26–34
106. van der Walt JM, Noureddine MA, Kittappa R, Hauser MA,
Scott WK, McKay R, Zhang F, Stajich JM, Fujiwara K, Scott
BL, Pericak-Vance MA, Vance JM, Martin ER (2004) Fibrob-
last growth factor 20 polymorphisms and haplotypes strongly
influence risk of Parkinson disease. Am J Hum Genet
74:1121–1127
107. Xu X, Wang N, Xu H, Xie A, Jiang H, Xie J (2013) Fibroblast
growth factor 20 polymorphism in sporadic Parkinson’s disease
in Northern Han Chinese. J Clin Neurosci 20:1588–1590
108. Grothe C, Timmer M (2007) The physiological and pharmaco-
logical role of basic fibroblast growth factor in the dopaminergic
nigrostriatal system. Brain Res Rev 54:80–91
109. Canto´ C, Auwerx J (2012) Cell biology. FGF21 takes a fat bite.
Science 336:675–676
110. Zhang F, Yu L, Lin X, Cheng P, He L, Li X, Lu X, Tan Y, Yang
H, Cai L, Zhang C (2015) Minireview: roles of fibroblast growth
factors 19 and 21 in metabolic regulation and chronic diseases.
Mol Endocrinol 26:me20151155
111. Kuro-o M (2008) Endocrine FGFs and Klothos: emerging con-
cepts. Trends Endocrinol Metab 19:239–245
112. Suomalainen A, Elo JM, Pietila¨inen KH, Hakonen AH, Sevas-
tianova K, Korpela M, Isohanni P, Marjavaara SK, Tyni T,
Kiuru-Enari S, Pihko H, Darin N, O˜unap K, Kluijtmans LA,
Paetau A, Buzkova J, Bindoff LA, Annunen-Rasila J, Uusimaa
J, Rissanen A, Yki-Ja¨rvinen H, Hirano M, Tulinius M, Smeitink
J, Tyynismaa H (2011) FGF-21 as a biomarker for muscle-
manifesting mitochondrial respiratory chain deficiencies: a
diagnostic study. Lancet Neurol 10:806–818
113. Hsuchou H, Pan W, Kastin AJ (2007) The fasting polypeptide
FGF21 can enter brain from blood. Peptides 28:2382–2386
114. Zhang Y, Xie Y, Berglund ED, Coate KC, He TT, Katafuchi T,
Xiao G, Potthoff MJ, Wei W, Wan Y, Yu RT, Evans RM,
Kliewer SA, Mangelsdorf DJ (2012) The starvation hormone,
fibroblast growth factor-21, extends lifespan in mice. Elife
1:e00065
115. Ma¨kela¨ J, Tselykh TV, Maiorana F, Eriksson O, Do HT, Mudo`
G, Korhonen LT, Belluardo N, Lindholm D (2014) Fibroblast
growth factor-21 enhances mitochondrial functions and increa-
ses the activity of PGC-1a in human dopaminergic neurons via
Sirtuin-1. Springerplus 3:2. doi:10.1186/2193-1801-3-2
116. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang
L, Culler MD, Coy DH (1989) Isolation of a novel 38 residue-
hypothalamic polypeptide which stimulates adenylate cyclase in
pituitary cells. Biochem Biophys Res Commun 164:567–574
117. Arimura A, Somogyvari-Vigh A, Weill C, Fiore RC, Tatsuno I,
Bay V, Brenneman DE (1994) PACAP functions as a neu-
rotrophic factor. Ann N Y Acad Sci 739:228–243
118. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D,
Wurtz O, Fournier A, Chow BK, Hashimoto H, Galas L, Vaudry
H (2009) Pituitary adenylate cyclase-activating polypeptide and
its receptors: 20 years after the discovery. Pharmacol Rev
61:283–357
119. Reglodi D, Kiss P, Lubics A, Tamas A (2011) Review on the
protective effects of PACAP in models of neurodegenerative
diseases in vitro and in vivo. Curr Pharm Des 17:962–972
120. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J,
Seeburg PH, Journot L (1993) Differential signal transduction
by five splice variants of the PACAP receptor. Nature
365:170–175
121. Wang G, PanJ TanYY, SunXK ZhangYF, ZhouHY RenRJ,
WangXJ Chen SD (2008) Neuroprotective effects of PACAP27
in mice model of Parkinson’s disease involved in the modulation
of K(ATP) subunits and D2 receptors in the striatum. Neu-
ropeptides 42:267–276
122. Lee EH, Seo SR (2014) Neuroprotective roles of pituitary
adenylate cyclase-activating polypeptide in neurodegenerative
diseases. BMB Rep 47:369–375
123. Lee FS, Rajagopal R, Kim AH, Chang PC, Chao MV (2002) Acti-
vation of Trk neurotrophin receptor signaling by pituitary adenylate
cyclase-activating polypeptides. J Biol Chem 277:9096–9102
124. Takei N, Skoglosa Y, Lindholm D (1998) Neurotrophic and
neuroprotective effects of pituitary adenylate cyclase-activating
polypeptide (PACAP) on mesencephalic dopaminergic neurons.
J Neurosci Res 54:698–706
125. Chung CY, Seo H, Sonntag KC, Brooks A, Lin L, Isacson O
(2005) Cell type-specific gene expression of midbrain
dopaminergic neurons reveals molecules involved in their vul-
nerability and protection. Hum Mol Genet 14:1709–1725
126. Reglodi D, Kiss P, Szabadfi K, Atlasz T, Gabriel R, Horvath G,
SzakalyP Sandor B, Lubics A, Laszlo E, Farkas J, Matkovits A,
Brubel R, Hashimoto H, Ferencz A, Vincze A, Helyes Z, Welke
L, Lakatos A, Tamas A (2012) PACAP is an endogenous pro-
tective factor-insights from PACAP-deficient mice. J Mol
Neurosci 48:482–492
127. Watson MB, Nobuta H, Abad C, Lee SK, Bala N, Zhu C,
Richter F, Chesselet MF, Waschek JA (2013) PACAP defi-
ciency sensitizes nigrostriatal dopaminergic neurons to
paraquat-induced damage and modulates central and peripheral
inflammatory activation in mice. Neuroscience 240:277–286
128. Delgado M, Leceta J, Ganea D (2003) Vasoactive intestinal
peptide and pituitary adenylate cyclase-activating polypeptide
inhibit the production of inflammatory mediators by activated
microglia. J Leukoc Biol 73:155–164
129. Ma¨kela¨ J, Koivuniemi R, Korhonen L, Lindholm D (2010)
Interferon-gamma produced by microglia and the neuropeptide
PACAP have opposite effects on the viability of neural pro-
genitor cells. PLoS One 5:e11091
130. Banks WA, Kastin AJ, Komaki G, Arimura A (1993) Passage of
pituitary adenylate cyclase activating polypeptide1-27 and
pituitary adenylate cyclase activating polypeptide1-38 across the
blood-brain barrier. J Pharmacol Exp Ther 267:690–696
131. Dogrukol-Ak D, Tore F, Tuncel N (2004) Passage of VIP/
PACAP/secretin family across the blood-brain barrier: thera-
peutic effects. Curr Pharm Des 10:1325–1340
Current disease modifying approaches to treat Parkinson’s disease 1379
123
